CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 60 enrolled
Drug / intervention
Savolitinib +1 moredrug
Likely dose
Savolitinib 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03091192
NCT03091192Phase 3Active
CompareCT.gov

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

AstraZeneca·interventional·Posted Mar 27, 2017·Updated Apr 14, 2026

In Brief

A Phase 3 clinical trial evaluating Savolitinib and Sunitinib for Carcinoma and 7 related conditions. Active but no longer recruiting, targeting 60 participants across 59 sites in 7 countries.

Detailed Summary

This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
CountriesBrazil, France, Italy, Russia, South Korea, Ukraine, United States
CollaboratorsHutchison Medipharma Limited

Timeline

Phase 3Active
20172018201920202021202220232024202520262027
First PostedMar 27, 2017
Enrollment StartJul 25, 2017
Primary CompletionAug 18, 2019
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.3 years ago

Interventions

Savolitinibdrug

600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously

Sunitinibdrug

50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off